The high 87.5% market-implied probability against Eli Lilly signing a commercial licensing or technology transfer agreement for Peptron’s SmartDepot microsphere platform by October 7 reflects the strictly non-binding character of their October 2024 evaluation deal. That pact grants only a non-exclusive internal R&D license for joint formulation work on Lilly’s peptide candidates, including GLP-1 agents for obesity and expanded CNS indications, with Lilly retaining the right to terminate on 30 days’ notice. No binding commercial rights have been announced despite nearly two years of in-vivo studies and initial validation, while Lilly has separately advanced long-acting delivery via Camurus’ FluidCrystal technology. The short window to the deadline and absence of prior signals reinforce trader consensus that the evaluation phase will conclude without a transition to full licensing.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · DiperbaruiEli Lilly licenses Peptron’s SmartDepot by October 7?
Eli Lilly licenses Peptron’s SmartDepot by October 7?
13% peluang
$11,414 Vol.
$11,414 Vol.
Oct 6, 2026
13% peluang
$11,414 Vol.
$11,414 Vol.
Oct 6, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.The high 87.5% market-implied probability against Eli Lilly signing a commercial licensing or technology transfer agreement for Peptron’s SmartDepot microsphere platform by October 7 reflects the strictly non-binding character of their October 2024 evaluation deal. That pact grants only a non-exclusive internal R&D license for joint formulation work on Lilly’s peptide candidates, including GLP-1 agents for obesity and expanded CNS indications, with Lilly retaining the right to terminate on 30 days’ notice. No binding commercial rights have been announced despite nearly two years of in-vivo studies and initial validation, while Lilly has separately advanced long-acting delivery via Camurus’ FluidCrystal technology. The short window to the deadline and absence of prior signals reinforce trader consensus that the evaluation phase will conclude without a transition to full licensing.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Pasar Dibuka: May 5, 2026, 8:02 PM ET
Volume
$11,414Tanggal Berakhir
Oct 7, 2026Pasar Dibuka
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.The high 87.5% market-implied probability against Eli Lilly signing a commercial licensing or technology transfer agreement for Peptron’s SmartDepot microsphere platform by October 7 reflects the strictly non-binding character of their October 2024 evaluation deal. That pact grants only a non-exclusive internal R&D license for joint formulation work on Lilly’s peptide candidates, including GLP-1 agents for obesity and expanded CNS indications, with Lilly retaining the right to terminate on 30 days’ notice. No binding commercial rights have been announced despite nearly two years of in-vivo studies and initial validation, while Lilly has separately advanced long-acting delivery via Camurus’ FluidCrystal technology. The short window to the deadline and absence of prior signals reinforce trader consensus that the evaluation phase will conclude without a transition to full licensing.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$11,414Tanggal Berakhir
Oct 7, 2026Pasar Dibuka
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...The high 87.5% market-implied probability against Eli Lilly signing a commercial licensing or technology transfer agreement for Peptron’s SmartDepot microsphere platform by October 7 reflects the strictly non-binding character of their October 2024 evaluation deal. That pact grants only a non-exclusive internal R&D license for joint formulation work on Lilly’s peptide candidates, including GLP-1 agents for obesity and expanded CNS indications, with Lilly retaining the right to terminate on 30 days’ notice. No binding commercial rights have been announced despite nearly two years of in-vivo studies and initial validation, while Lilly has separately advanced long-acting delivery via Camurus’ FluidCrystal technology. The short window to the deadline and absence of prior signals reinforce trader consensus that the evaluation phase will conclude without a transition to full licensing.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui
Hati-hati dengan link eksternal.
Hati-hati dengan link eksternal.
Pertanyaan yang Sering Diajukan